PT1729810T - Métodos de redução da agregação de il-ira - Google Patents
Métodos de redução da agregação de il-iraInfo
- Publication number
- PT1729810T PT1729810T PT05733155T PT05733155T PT1729810T PT 1729810 T PT1729810 T PT 1729810T PT 05733155 T PT05733155 T PT 05733155T PT 05733155 T PT05733155 T PT 05733155T PT 1729810 T PT1729810 T PT 1729810T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- reducing aggregation
- aggregation
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55916104P | 2004-04-02 | 2004-04-02 | |
| US55887904P | 2004-04-02 | 2004-04-02 | |
| US60121604P | 2004-08-12 | 2004-08-12 | |
| US60122904P | 2004-08-12 | 2004-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1729810T true PT1729810T (pt) | 2018-11-22 |
Family
ID=34964860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05733155T PT1729810T (pt) | 2004-04-02 | 2005-04-01 | Métodos de redução da agregação de il-ira |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7619066B2 (pt) |
| EP (1) | EP1729810B1 (pt) |
| JP (3) | JP2007531738A (pt) |
| AU (1) | AU2005231822B2 (pt) |
| CA (1) | CA2557910C (pt) |
| CY (1) | CY1120831T1 (pt) |
| DK (1) | DK1729810T3 (pt) |
| ES (1) | ES2694252T3 (pt) |
| HR (1) | HRP20181848T1 (pt) |
| HU (1) | HUE040595T2 (pt) |
| LT (1) | LT1729810T (pt) |
| PL (1) | PL1729810T3 (pt) |
| PT (1) | PT1729810T (pt) |
| RS (1) | RS57852B1 (pt) |
| SI (1) | SI1729810T1 (pt) |
| TR (1) | TR201816556T4 (pt) |
| WO (1) | WO2005097195A2 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820680B2 (en) * | 2004-03-09 | 2010-10-26 | Merck & Co., Inc. | HIV integrase inhibitors |
| HUE040595T2 (hu) * | 2004-04-02 | 2019-03-28 | Swedish Orphan Biovitrum Ab Publ | Eljárás IL-1ra aggregációjának csökkentésére |
| US10105441B2 (en) * | 2007-08-16 | 2018-10-23 | The Schepens Eye Research Institute, Inc. | Method for inhibiting or reducing dry eye disease by IL-1Ra |
| CN101690801B (zh) * | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
| EP2598526B1 (en) | 2010-07-29 | 2018-09-05 | Eleven Biotherapeutics, Inc. | Chimeric il-1 receptor type i agonists and antagonists |
| PL2672985T3 (pl) * | 2011-02-11 | 2016-11-30 | Bezcytrynianowe kompozycje farmaceutyczne zawierające anakinrę | |
| RU2013145283A (ru) | 2011-03-14 | 2015-04-20 | Флого АпС | Новые антагонисты рецептора интерлейкина-1 |
| WO2013019652A1 (en) * | 2011-07-29 | 2013-02-07 | Eleven Biotherapeutics, Inc. | Purified proteins |
| WO2013184942A1 (en) | 2012-06-08 | 2013-12-12 | Alkermes, Inc. | Ligands modified by circular permutation as agonists and antagonists |
| DK2968468T3 (en) * | 2013-03-13 | 2021-07-26 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
| US20160129112A1 (en) * | 2013-05-28 | 2016-05-12 | Momenta Pharmaceuticals, Inc. | Pharmaceutical Compositions Comprising Pyrophosphate |
| KR102582560B1 (ko) | 2015-04-28 | 2023-09-26 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 아나킨라를 포함하는 조성물 |
| EP3551650A4 (en) * | 2016-12-07 | 2020-07-08 | The University of Florida Research Foundation Incorporated | IL-1RA-CDNAS |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226846A (en) * | 1977-04-01 | 1980-10-07 | New England Nuclear Corporation | Albumin microaggregates for radioactive scanning of reticuloendothelial systems |
| EP0569687B1 (en) * | 1984-05-18 | 2002-08-21 | New England Medical Center Hospitals, Inc. | Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins |
| US4935343A (en) * | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| US5359032A (en) * | 1987-08-26 | 1994-10-25 | Biogen Inc. | Interkeukin-1 inhibitor |
| US5296592A (en) | 1987-11-25 | 1994-03-22 | Immunex Corporation | Process for purifying interleukin-1 receptors |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US6511665B1 (en) | 1987-11-25 | 2003-01-28 | Immunex Corporation | Antibodies to interleukin-1 receptors |
| WO1989004838A1 (en) * | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
| US5081228A (en) | 1988-02-25 | 1992-01-14 | Immunex Corporation | Interleukin-1 receptors |
| US5075222A (en) * | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| CA2010321C (en) * | 1989-02-21 | 2004-04-06 | Thomas F. Tedder | Lymphocyte-associated cell surface protein |
| AU651955B2 (en) | 1989-11-29 | 1994-08-11 | Amgen, Inc. | Production of recombinant human interleukin-1 inhibitor |
| WO1992011359A1 (en) | 1990-12-20 | 1992-07-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | A truncated interleukin-1 receptor gene for the treatment of arthritis |
| US5591457A (en) | 1992-02-07 | 1997-01-07 | Vasogen Inc | Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human |
| US5980954A (en) | 1992-02-07 | 1999-11-09 | Vasogen Ireland Limited | Treatment of autoimmune diseases |
| CZ291261B6 (cs) * | 1992-09-17 | 2003-01-15 | Amgen Inc. | Farmaceutická kompozice pro léčení nemocí zprostředkovaných interleukinem-1 |
| US6242417B1 (en) * | 1994-03-08 | 2001-06-05 | Somatogen, Inc. | Stabilized compositions containing hemoglobin |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5580856A (en) * | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
| PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| CZ299025B6 (cs) * | 1996-02-09 | 2008-04-02 | Amgen Inc. | Farmaceutická kompozice a její použití |
| US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6416753B1 (en) * | 1996-03-15 | 2002-07-09 | The General Hospital Corporation | Method for modulating apoptosis |
| WO1998008969A1 (en) | 1996-08-26 | 1998-03-05 | Human Genome Sciences, Inc. | Soluble interleukin-1 receptor accessory molecule |
| US5780431A (en) | 1996-09-20 | 1998-07-14 | Neurobiological Technologies, Inc. | Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form |
| US6054559A (en) | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| US6541623B1 (en) | 1998-04-03 | 2003-04-01 | Hyseq, Inc. | Interleukin—1 receptor antagonist and uses thereof |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU2915801A (en) | 1999-09-07 | 2001-05-10 | Colorado State University Research Foundation | In vivo treatment of joint disease using interleukin-1 receptor antagonists |
| WO2001019390A1 (en) | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| US6323311B1 (en) * | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
| WO2001024814A1 (en) | 1999-10-04 | 2001-04-12 | Chiron Corporation | Stabilized liquid polypeptide-containing pharmaceutical compositions |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| CN1549723A (zh) * | 2001-02-06 | 2004-11-24 | Ĭ��ר������˾ | 免疫原性减弱的经修饰白介素-1受体拮抗剂(il-1ra) |
| US7572770B2 (en) * | 2002-06-27 | 2009-08-11 | University Of Zurich | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| CA2497884C (en) | 2002-09-06 | 2013-10-22 | Brian Varnum | Therapeutic human anti-il-1r1 monoclonal antibody |
| EP3777880A1 (en) * | 2003-02-10 | 2021-02-17 | Biogen MA Inc. | Immunoglobulin formulation and method of preparation thereof |
| US20050159590A1 (en) * | 2003-08-25 | 2005-07-21 | Galit Rotman | Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
| HUE040595T2 (hu) * | 2004-04-02 | 2019-03-28 | Swedish Orphan Biovitrum Ab Publ | Eljárás IL-1ra aggregációjának csökkentésére |
-
2005
- 2005-04-01 HU HUE05733155A patent/HUE040595T2/hu unknown
- 2005-04-01 PL PL05733155T patent/PL1729810T3/pl unknown
- 2005-04-01 RS RS20181312A patent/RS57852B1/sr unknown
- 2005-04-01 SI SI200532236T patent/SI1729810T1/sl unknown
- 2005-04-01 TR TR2018/16556T patent/TR201816556T4/tr unknown
- 2005-04-01 DK DK05733155.5T patent/DK1729810T3/en active
- 2005-04-01 AU AU2005231822A patent/AU2005231822B2/en active Active
- 2005-04-01 EP EP05733155.5A patent/EP1729810B1/en active Active
- 2005-04-01 CA CA2557910A patent/CA2557910C/en active Active
- 2005-04-01 PT PT05733155T patent/PT1729810T/pt unknown
- 2005-04-01 WO PCT/US2005/011332 patent/WO2005097195A2/en not_active Application Discontinuation
- 2005-04-01 US US11/097,453 patent/US7619066B2/en active Active
- 2005-04-01 US US11/097,993 patent/US10765747B2/en active Active
- 2005-04-01 ES ES05733155.5T patent/ES2694252T3/es active Active
- 2005-04-01 LT LTEP05733155.5T patent/LT1729810T/lt unknown
- 2005-04-01 JP JP2007506351A patent/JP2007531738A/ja not_active Withdrawn
-
2013
- 2013-01-24 JP JP2013011368A patent/JP6181375B2/ja active Active
-
2014
- 2014-11-05 JP JP2014224940A patent/JP6041843B2/ja active Active
-
2018
- 2018-10-30 CY CY181101118T patent/CY1120831T1/el unknown
- 2018-11-06 HR HRP20181848TT patent/HRP20181848T1/hr unknown
-
2020
- 2020-07-31 US US16/945,494 patent/US20210121571A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005231822B2 (en) | 2011-07-21 |
| ES2694252T3 (es) | 2018-12-19 |
| DK1729810T3 (en) | 2018-12-03 |
| CY1120831T1 (el) | 2019-12-11 |
| US7619066B2 (en) | 2009-11-17 |
| CA2557910A1 (en) | 2005-10-20 |
| PL1729810T3 (pl) | 2019-02-28 |
| JP2007531738A (ja) | 2007-11-08 |
| US20050271618A1 (en) | 2005-12-08 |
| SI1729810T1 (sl) | 2018-12-31 |
| LT1729810T (lt) | 2018-11-26 |
| US10765747B2 (en) | 2020-09-08 |
| CA2557910C (en) | 2012-05-29 |
| TR201816556T4 (tr) | 2018-11-21 |
| HRP20181848T1 (hr) | 2018-12-28 |
| EP1729810A2 (en) | 2006-12-13 |
| HUE040595T2 (hu) | 2019-03-28 |
| EP1729810B1 (en) | 2018-08-15 |
| JP2015078195A (ja) | 2015-04-23 |
| JP6181375B2 (ja) | 2017-08-16 |
| JP6041843B2 (ja) | 2016-12-14 |
| JP2013136588A (ja) | 2013-07-11 |
| WO2005097195A3 (en) | 2006-08-03 |
| US20070098684A9 (en) | 2007-05-03 |
| US20210121571A1 (en) | 2021-04-29 |
| WO2005097195A2 (en) | 2005-10-20 |
| AU2005231822A1 (en) | 2005-10-20 |
| RS57852B1 (sr) | 2018-12-31 |
| US20050282752A1 (en) | 2005-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181848T1 (hr) | Postupci smanjenja agregacije il-1ra | |
| ME02245B (me) | Anti-cd38 humana antitjela i njihove upotrebe | |
| HK1159500A1 (en) | Methods for purifying trans-(-)-delta9-tetrahydrocannabinol and trans-()- delta9-tetrahydrocannabinol -(-)-9--()-9- | |
| SI2511297T1 (sl) | Proti -CD38 humana protitelesa in njihova uporaba | |
| IL176958A0 (en) | Compounds and methods of use | |
| EP1769402A4 (en) | ECOSYSTEM PROCESS FOR AGGREGATING AND SEARCHING AND RELATED TECHNIQUES | |
| SI1802579T1 (sl) | Derivati 3-arilaminopiridina | |
| IL178164A0 (en) | Single crystals and methods for fabricating same | |
| SG117621A1 (en) | Methods for enhancing the formation of nickel mono-silicide by reducing the formation of nickel di-silicide | |
| EP1812451A4 (en) | COMPOUNDS AND METHODS OF USE THEREOF | |
| IL181507A0 (en) | Methods for making retinoids and uses thereof | |
| PL2215908T3 (pl) | 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów | |
| EP1737565A4 (en) | COS CLAUS CONFIGURATIONS AND METHODS | |
| GB0428291D0 (en) | Methods of regenerating NOx-Absorbent | |
| IL178683A0 (en) | Methods of diminishing co-abuse potenitial | |
| PL372911A1 (en) | Vitamin mixture | |
| ZA200610295B (en) | Anti-IL-13 antibodies, crystals of anti-IL-13 antibodies and complexes comprising them | |
| GB2444371B (en) | Fuctionalised interface refreshing | |
| GB0428347D0 (en) | Oedema reduction | |
| GB0411417D0 (en) | Magic method | |
| GB0308410D0 (en) | Cell aggregation | |
| AU2004905174A0 (en) | Method of shopping | |
| GB0406358D0 (en) | Aircraft personal audio interface |